{"name":"Nuo Therapeutics","slug":"nuo","ticker":"NRTI","exchange":"OTC","domain":"nuotherapeutics.com","description":"Nuo Therapeutics is a medical device company focused on developing innovative solutions for wound care. The company's top products include its proprietary electroceutical technology, which has shown promise in treating chronic wounds. Nuo Therapeutics is a relatively small player in the wound care market, but its technology has garnered attention from investors and clinicians alike.","hq":"Reston, VA","founded":0,"employees":"","ceo":"Hojabr Alimi","sector":"Medical Devices / Wound Care","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$5M","metrics":{"revenue":1000000,"revenueGrowth":52.6,"grossMargin":0,"rdSpend":0,"netIncome":-2323705,"cash":1189508,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2014-02-28","type":"earnings","headline":"Nuo Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results","summary":"Nuo Therapeutics reported its financial results for the fourth quarter and full year 2013, which showed a net loss of $4.4 million.","drugName":"","sentiment":"neutral"},{"date":"2013-04-01","type":"regulatory","headline":"Nuo Therapeutics Receives FDA Clearance for its Electroceutical Device","summary":"Nuo Therapeutics announced that it had received FDA clearance for its electroceutical device, which is designed to treat chronic wounds.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-01-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-30","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Smith & Nephew","3M","Johnson & Johnson"],"therapeuticFocus":["Wound Care"],"financials":{"source":"sec_edgar+yahoo","revenue":721045,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":721045,"period":"2017-12-31"},{"value":472445,"period":"2016-12-31"},{"value":472445,"period":"2016-12-31"},{"value":11510977,"period":"2015-12-31"},{"value":7761934,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":0,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-2323705,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1189508,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}